#391
|
|||
|
|||
Öèòàòà:
P.S.çàáûë ïðî àíòèêîàãóëÿöèþ |
#392
|
||||
|
||||
Î2 ðàçóìååòñÿ èäåò... ôåíèëýôðèí ïàðàëåëüíî äîáóòàìèíó øåë ñ íà÷àëó è (èäåò?) - ïðîñòî åñëè ìû èìååì (?) ïëîõîé âûáðîñ- íå ïðèâåäåò ëè îäèí ìåçàòîí ê óõóäüøåíèþ çà ñ÷åò âîçðàñòàíèÿ ÎÏÑÑ??
|
#393
|
||||
|
||||
Õîòü ñòðåëÿéòå, íå ïîíèìàþ, çà÷åì âàì àìèîäàðîí?
|
#394
|
||||
|
||||
Öèòàòà:
(ìîæ ïîòîìó êàê àìèîäàðîí ìåíüøå íà àä áóäåò âëèÿòü?) |
#395
|
||||
|
||||
Àìèîäàðîí äëÿ êîíòðîëÿ ×ÑÑ íåò ñìûñëà íàçíà÷àòü, òåì áîëåå, ÷òî åñòü ðèñê âîññòàíîâëåíèÿ ðèòìà (îò íåãî), ìîæíî åùå ÷òî-íèáóäü ïîëó÷èòü. Ïîýòîìó, íà ìîé âçãëÿä, äèãîêñèí, à çàòåì ïîñëå äîñòèæåíèÿ òåðïèìûõ öèôð ÀÄ - äîáàâèòü êîðîòêîäåéñòâóþùèé ÁÀÁ. Ìû âî âñÿêîì ñëó÷àå êîðäàðîí íèêîãäà äëÿ êîíòðîëÿ ×ÑÑ íå èñïîëüçóåì.
|
#396
|
|||
|
|||
Öèòàòà:
Department of Veterans Affairs Medical Center, West Los Angeles, Calif 90073, USA. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] BACKGROUND: The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial. METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4.5 years. The primary end point was the time to recurrence of atrial fibrillation beginning on day 28, determined by means of weekly transtelephonic monitoring. RESULTS: Spontaneous conversion occurred in 27.1 percent of the amiodarone group, 24.2 percent of the sotalol group, and 0.8 percent of the placebo group, and direct-current cardioversion failed in 27.7 percent, 26.5 percent, and 32.1 percent, respectively. The median times to a recurrence of atrial fibrillation were 487 days in the amiodarone group, 74 days in the sotalol group, and 6 days in the placebo group according to intention to treat and 809, 209, and 13 days, respectively, according to treatment received. Amiodarone was superior to sotalol (P<0.001) and to placebo (P<0.001), and sotalol was superior to placebo (P<0.001). In patients with ischemic heart disease, the median time to a recurrence of atrial fibrillation was 569 days with amiodarone therapy and 428 days with sotalol therapy (P=0.53). Restoration and maintenance of sinus rhythm significantly improved the quality of life and exercise capacity. There were no significant differences in major adverse events among the three groups. CONCLUSIONS: Amiodarone and sotalol are equally efficacious in converting atrial fibrillation to sinus rhythm. Amiodarone is superior for maintaining sinus rhythm, but both drugs have similar efficacy in patients with ischemic heart disease. Sustained sinus rhythm is associated with an improved quality of life and improved exercise performance. Copyright 2005 Massachusetts Medical Society. Publication Types: * Clinical Trial * Multicenter Study * Randomized Controlled Trial PMID: 15872201 [PubMed - indexed for MEDLINE] Åñëè âîññòàíîâèòñÿ ñèíóñ - áóäåò íàìíîãî ïðîøå ñ ÀÄ.Íå âîññòàíîâèòüñÿ- â ïîíåäåëüíèê âñå-ðàâíî áóäóò áîëüíîãî " ñòó÷àòü" - è àìèî äëÿ ïîääåðæàíèÿ ñèíóñà - ïðåïàðàò âûáîðà |
#397
|
|||
|
|||
Äëÿ Âàäèìà
Öèòàòà:
|
#398
|
||||
|
||||
äèëÿòàöèîííàÿ êàðäèîìèîïàòèÿ, âîáùåì íà ìåçàòîíå è äîáóòàìèíå...
ñïàñèá âñåì êòî îòêëèêíóëñÿ..... |
#399
|
||||
|
||||
Öèòàòà:
Ýòî áûë îäèí èç ïðåäïîëàãàåìûõ âàðèàíòîâ. Èäåÿ ïðèíàäëåæàëà Èâàíó Òèìîôååâè÷ó. |
#400
|
||||
|
||||
Ïîëó÷àåòñÿ, ÷òî êîðäàðîí áûë íå íóæåí, à äèãîêñèí â ñàìûé ðàç.
Óâàæàåìûé, reopoliglucin, ïîèíòåðåñóéòåñü ïîæàëóéñòà, èç ñïîðòèâíîãî èíòåðåñà, íå áûë ëè áîëüíîé âîäèòåëåì òðàíñïîðòà ïî ïðîôåññèè. |
#401
|
||||
|
||||
Âû åãî çíàëè?
|
#402
|
||||
|
||||
Î íåò, ïðîñòî åñòü íåáîëüøàÿ òåîðèÿ. Òàê îí âîäèòåëü?
|
#403
|
||||
|
||||
äà- ñëóæèò âîäèòåëåì
|
#404
|
||||
|
||||
Íàøà ñîáñòâåííàÿ òåîðèÿ, êîòîðîé ïîêà íåò îáúÿñíåíèÿ, íî åñòü ïîäòâåðæäåíèå â ïðàêòèêå. Åñëè ìóæ÷èíà â âîçðàñòå ñòàðøå 40 ëåò ïðåäúÿâëÿåò æàëîáû íà ñèëüíóþ îäûøêó, èìååòñÿ ìåðöàòåëüíàÿ àðèòìèÿ, ðàáîòàåò âîäèòåëåì, òî âûñîêà âåðîÿòíîñòü ÄÊÌÏ, îñîáåííî åñëè âûïèâàåò. Ó íàñ áûëî ñòîëüêî ïðèìåðîâ, ÷òî óæå äèññåðòàöèþ ìîæíî çàùèòèòü. Ìû èõ äàæå ïî âíåøíåìó âèäó ñòàëè âûÿâëÿòü.
|
#405
|
||||
|
||||
Öèòàòà:
|